← Eichor
Condition: Hr Her2 Early Breast Cancer Synced from ClinicalTrials.gov · July 28, 2026

Recruiting studies: Hr Her2 Early Breast Cancer

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

Dalpiciclib With or Without Entinostat and Letrozole in HR+/HER2- Early Breast Cancer
Phase 2 · 1 location(s) · Hebei Medical University Fourth Hospital · NCT07492394Patient Relevant Outcomes Improvement Program in High Risk Hormone Receptor Positive (HR+) Breast Cancer
Phase N/A · 1 location(s) · Institut fuer Frauengesundheit · NCT07531693CDK4/6 Inhibitors Combined With Standard Adjuvant Endocrine Therapy in High-Risk, HR+/HER2+ Early Breast Cancer Patients
Phase 3 · 1 location(s) · Fudan University · NCT07019363A Non-interventional Study for Kisqali (Ribociclib) in Combination With an Aromatase Inhibitor for Adjuvant Treatment in
Phase N/A · 284 location(s) · Novartis Pharmaceuticals · NCT06830720Efficacy and Safety of Dalpiciclib With Endocrine Therapy as Adjuvant Treatment in HR+/ HER2- Early Breast Cancer
Phase 2 · 1 location(s) · The First Affiliated Hospital with Nanjing Medical Universit · NCT06341894Evaluating the Effectiveness of Typology-based Coaching on Patients' Therapy Management
NA · 3 location(s) · Institut fuer Frauengesundheit · NCT07708571Impact of Endocrine Therapy, Menstrual Cycle, PAM50, Ki67 on Treatment Decisions in HR+ and HER2- Breast Cancer
Phase N/A · 1 location(s) · University Hospital Tuebingen · NCT05878314The Efficiency for Stage II-III HR+/HER2+ Early Breast Cancer Patient With Standard Neoadjuvant Therapy in Real World.
Phase N/A · 1 location(s) · Shengjing Hospital · NCT05263570Trastuzumab Deruxtecan Alone or in Combination With Anastrozole for the Treatment of Early Stage HER2 Low, Hormone Recep
Phase 2 · 9 location(s) · Jonsson Comprehensive Cancer Center · NCT04553770PROOFS-Registry - Premenopausal Women With Breast Cancer Optimally Treated With OFS
Phase N/A · 71 location(s) · West German Study Group · NCT05792150Phase IIIb Study of Ribociclib + ET in Early Breast Cancer
Phase 3 · 229 location(s) · Novartis Pharmaceuticals · NCT05827081Impact of Intermittent Fasting on Biomarkers of Inflammation and Health-Related Quality of Life: A Feasibility Trial for
NA · 1 location(s) · Medical College of Wisconsin · NCT06106477Adherence to Aromatase Inhibitors ± Abemaciclib Treatment in Patients With Early-stage HER2-negative Breast Cancer
Phase N/A · 1 location(s) · Institute of Oncology Ljubljana · NCT06650423RADIANT: Pre-op Radiation With Abemaciclib and Letrozole
Phase 1 · 4 location(s) · Mridula George, MD · NCT06139107A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032)
Phase 3 · 317 location(s) · Merck Sharp & Dohme LLC · NCT06966700Efficacy and Safety of Culmerciclib Plus Aromatase Inhibitors in a Response-Adapted Neoadjuvant Strategy for Highly Prol
Phase 2 · 1 location(s) · Second Affiliated Hospital, School of Medicine, Zhejiang Uni · NCT07616453ctDNA-Guided De-Escalation of Adjuvant Chemotherapy With Dalpiciclib in HR-Positive/HER2-Negative Breast Cancer
Phase 2 · 1 location(s) · Peking University People's Hospital · NCT06970912NabPE With or Without Serplulimab for Early-stage HR+/HER2- Breast Cancer.
Phase N/A · 1 location(s) · Henan Cancer Hospital · NCT06781281Neoadjuvant SNF Precision Therapy Phase III
Phase 3 · 1 location(s) · Fudan University · NCT06913777Signatera-Guided CDK4/6 Inhibitor Therapy in Breast Cancer
NA · 39 location(s) · Natera, Inc. · NCT07214532Serplulimab Combined With Chemotherapy for Early-stage HR+/HER2- Breast Cancer
Phase 2 · 1 location(s) · Henan Cancer Hospital · NCT06860529Fovinaciclib Plus Aromatase Inhibitors and Dual HER2 Blockade in a Response-Adapted Neoadjuvant Strategy for HR-Positive
Phase 2 · 3 location(s) · Second Affiliated Hospital, School of Medicine, Zhejiang Uni · NCT07616427ABCSG 61 / TEODOR : Neoadjuvant TrEatment Optimization Driven by Circulating Tumor DNA and endOcrine Responsiveness
NA · 14 location(s) · Austrian Breast & Colorectal Cancer Study Group · NCT07084558The Benefits of Continued Use of Ovarian Function Suppression After 5 Years
Phase N/A · 1 location(s) · Hongmei Zheng, PhD · NCT06050109Efficacy and Safety of Fluzoparib Combined With Adjuvant Endocrine Therapy for HR+/HER2- SNF3-subtype Early Breast Cance
Phase 3 · 15 location(s) · Fudan University · NCT05891093A Short-term Preoperative, Evaluating Activity and Safety of Elacestrant Monotherapy as Compared to Elacestrant + Ovaria
Phase 2 · 1 location(s) · Gustave Roussy, Cancer Campus, Grand Paris · NCT07159451FREDO-ODX Study: FREnch Data on Outcomes in HR+/HER2- Early Breast Cancer Patients With oncotypeDX Recurrence Score-guid
Phase N/A · 5 location(s) · Centre Hospitalier Universitaire de Besancon · NCT06185569RWE Non-Interventional Prospective Study of Ribociclib Effectiveness and Safety in Patients With HR+/HER2- Early Breast
Phase N/A · 2 location(s) · Novartis Pharmaceuticals · NCT06797531Ribociclib in Combination With Adjuvant Endocrine Therapy for Patients With Early High-risk HR+HER2- Breast Cancer
Phase N/A · 1 location(s) · Second Affiliated Hospital, School of Medicine, Zhejiang Uni · NCT06587789Evaluating Minimal Residual Disease (MRD) Through Longitudinal Circulating Tumor DNA (ctDNA) Profiling in Breast Maligna
Phase N/A · 14 location(s) · Tempus AI · NCT07211178
Look up another condition
Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.